ResearcherUniversity of California, IrvineActive in the last 2 years
Austin D. Silva
Matched on ORCID iD 0000-0001-5150-2551; OpenAlex author ID A5023009395, A5048119823. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 3 papers
Papers 6
- Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
- Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
- ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
- The pro-inflammatory cytokines IL-1β and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cancer cells. Co-author DOI 10.1016/j.jbc.2024.107752↗
- ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. Co-author DOI 10.1172/jci.insight.161563↗
- Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1074/jbc.ra120.014126↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher J. Halbrook · 3 shared papers, 2026 · strength 0.61
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Rima Singh · 3 shared papers, 2026 · strength 0.61
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Alica K. Michels · 3 shared papers, 2026 · strength 0.61
- Paper Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. DOI 10.1016/j.jcmgh.2026.101872↗
- Paper Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. DOI 10.1053/j.gastro.2026.09.027↗
- Paper ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. DOI 10.1158/0008-5472.can-26-0138↗
- Susan L Bellis · 3 shared papers, 2021–2024 · strength 0.58
- Paper The pro-inflammatory cytokines IL-1β and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cance… DOI 10.1016/j.jbc.2024.107752↗
- Paper ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. DOI 10.1172/jci.insight.161563↗
- Paper Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. DOI 10.1074/jbc.ra120.014126↗
- Michael P. Marciel · 2 shared papers, 2023–2024 · strength 0.45
- Alexander Kleger · 2 shared papers, 2026 · strength 0.38
- Thomas Theodor Werner Seufferlein · 2 shared papers, 2026 · strength 0.38
- Donald J Buchsbaum · 2 shared papers, 2021–2023 · strength 0.27
- Colleen M. Britain · 2 shared papers, 2021–2023 · strength 0.27
- Asmi Chakraborty · 2 shared papers, 2021–2023 · strength 0.27
- Nikita Bhalerao · 2 shared papers, 2021–2023 · strength 0.27
- Oliver Gene McDonald · 1 shared paper, 2026 · strength 0.23
- Nikki K. Lytle · 1 shared paper, 2026 · strength 0.23
- Nina G. Steele · 1 shared paper, 2026 · strength 0.23
- David K. Imagawa · 1 shared paper, 2026 · strength 0.23
- Ian M. Loveless · 1 shared paper, 2026 · strength 0.23
- Zeljka Jutric · 1 shared paper, 2026 · strength 0.23
- Mohammed Aldakkak · 1 shared paper, 2026 · strength 0.23
- Jennifer P. Morton · 1 shared paper, 2026 · strength 0.23
- Alexander Muir · 1 shared paper, 2026 · strength 0.20
- Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.20
- Chantal Allgöwer · 1 shared paper, 2026 · strength 0.20
- Tim Eiseler · 1 shared paper, 2026 · strength 0.20
- Kevin Christian Montecillo Gulay · 1 shared paper, 2026 · strength 0.20
- Aimee L Edinger · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.